Merck Is Maintained at Buy by Citigroup
Merck & Co Analyst Ratings
IBRX Soars 47% on Initial Trials For Cell Therapy Product
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Barclays Sticks to Its Buy Rating for Merck & Company (MRK)
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $135
Merck & Company (MRK) Receives a Buy From Berenberg Bank
Goldman Sachs Adjusts Price Target on Merck to $139 From $140
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings